ReviewSchizophrenia bulletin2013
Challenges in the treatment of major depressive disorder with psychotic features.
Review in Schizophrenia bulletin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 123 citations in OpenAlex.
- Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study.Neuropsychobiology · 2023Trial
- Trial
- The correlations between psychotic symptoms and childhood maltreatment as well as sex differences in adolescents with major depressive disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- Co-existence of clinical high-risk for psychosis and bipolar disorder: a multi-dimensional psychopathological analysis.BMC psychiatry · 2026Article
- Understanding Psychotic Depression.Advances in experimental medicine and biology · 2026Review
- Prevalence and associated factors of cognitive impairment among hospitalized older adults with depression: a cross-sectional study from a tertiary psychiatric hospital in Guangzhou, China.Frontiers in public health · 2026Article
- Prevalence and related factors of comorbid suicide attempts and psychotic symptoms in first-episode drug-naïve patients with major depressive disorder.BMC psychiatry · 2025Article
- Clinical Effectiveness of Electroconvulsive Therapy for Psychotic vs Nonpsychotic Depression: A Cohort Study.The Journal of clinical psychiatry · 2025Article
- Untangling Depression in Schizophrenia: The Role of Disorganized and Obsessive-Compulsive Symptoms and the Duration of Untreated Psychosis.Biomedicines · 2024Article
- Differences of regional homogeneity and cognitive function between psychotic depression and drug-naïve schizophrenia.BMC psychiatry · 2024Article
- Real-world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within-subject analyses of two nationwide cohorts.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2024Article
- [Coenzyme Q10 alleviates depression-like behaviors in mice with chronic restraint stress by down-regulating the pyroptosis signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Deep brain stimulation for refractory major depressive disorder: a comprehensive review.Molecular psychiatry · 2024Review
- Prevalence and risk factors for psychotic symptoms in young, first-episode and drug-naïve patients with major depressive disorder.BMC psychiatry · 2024Article
- Bipolar disorder and Lewy body dementia: case report and literature review.Frontiers in psychiatry · 2024Article
- The Role of Genetics in the Development and Pharmacotherapy of Depression and Its Impact on Drug Discovery.International journal of molecular sciences · 2023Review
- Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression.Brain sciences · 2023Article
- Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis.Neuropsychiatric disease and treatment · 2023Review
- Lipids in major depressive disorder: new kids on the block or old friends revisited?Frontiers in psychiatry · 2023Review
- Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment.IBRO neuroscience reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Psychotic depression is associated with significant morbidity and mortality but is underdiagnosed and undertreated. In recent years, there have been several studies that have increased our knowledge regarding the optimal treatment of patients with psychotic depression. The combination of an antidepressant and antipsychotic is significantly more effective than either antidepressant monotherapy or antipsychotic monotherapy for the acute treatment of psychotic depression. Most treatment guidelines recommend either the combination of an antidepressant with an antipsychotic or ECT for the treatment of an acute episode of unipolar psychotic depression. The optimal maintenance treatment after a person responds to either the antidepressant/antipsychotic combination or the ECT is unclear particularly as it pertains to length of time the patient needs to take the antipsychotic medication. Little is known regarding the optimal treatment of a patient with bipolar disorder who has an episode of psychotic depression or the clinical characteristics of responders to medication treatments vs ECT treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.